- Home
- IPHA vs RMAX Comparison
IPHA vs RMAX Comparison
Compare IPHA & RMAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- RMAX
- Stock Information
- Founded
- IPHA 1999
- RMAX 1973
- Country
- IPHA France
- RMAX United States
- Employees
- IPHA N/A
- RMAX N/A
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- RMAX Real Estate
- Sector
- IPHA Health Care
- RMAX Finance
- Exchange
- IPHA Nasdaq
- RMAX Nasdaq
- Market Cap
- IPHA 160.1M
- RMAX 187.5M
- IPO Year
- IPHA 2019
- RMAX 2013
- Fundamental
- Price
- IPHA $1.95
- RMAX $8.42
- Analyst Decision
- IPHA Hold
- RMAX Hold
- Analyst Count
- IPHA 2
- RMAX 1
- Target Price
- IPHA $2.00
- RMAX $9.00
- AVG Volume (30 Days)
- IPHA 21.4K
- RMAX 200.3K
- Earning Date
- IPHA 09-17-2025
- RMAX 10-30-2025
- Dividend Yield
- IPHA N/A
- RMAX N/A
- EPS Growth
- IPHA N/A
- RMAX N/A
- EPS
- IPHA N/A
- RMAX 0.48
- Revenue
- IPHA $14,839,695.00
- RMAX $298,162,000.00
- Revenue This Year
- IPHA $350.96
- RMAX N/A
- Revenue Next Year
- IPHA $32.92
- RMAX N/A
- P/E Ratio
- IPHA N/A
- RMAX $17.53
- Revenue Growth
- IPHA N/A
- RMAX N/A
- 52 Week Low
- IPHA $1.29
- RMAX $6.90
- 52 Week High
- IPHA $3.51
- RMAX $14.31
- Technical
- Relative Strength Index (RSI)
- IPHA 50.85
- RMAX 33.96
- Support Level
- IPHA $1.95
- RMAX $9.10
- Resistance Level
- IPHA $2.10
- RMAX $9.44
- Average True Range (ATR)
- IPHA 0.07
- RMAX 0.31
- MACD
- IPHA 0.02
- RMAX -0.18
- Stochastic Oscillator
- IPHA 66.09
- RMAX 1.57
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About RMAX RE/MAX Holdings Inc.
RE/MAX Holdings Inc operates as a franchisor of real estate brokerage services. It recruits and retains agents and sells franchises. The company's operating segments include Real Estate, Mortgage, Marketing Funds, and Others. It generates maximum revenue from the Real Estate segment.